CAMP4 THERAPEUTICS CORPORATION (CAMP) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CAMP4 THERAPEUTICS CORP

Financial Performance:

• Cash on hand stands at $124 million as of the end of Q3, providing runway through the end of 2028 to fund clinical milestones.
• No revenue currently generated; company remains in pre-revenue stage focused on clinical execution.
• Funding model relies on milestone and royalty payments from a strategic partnership with GSK for non-CNS indications.

Guidance and Future Outlook:

• First patient dosing in the Phase I/II SYNGAP1 trial expected by the end of the current year.
• Initial clinical data readout projected for the first half of 2028; no interim safety or PK data expected prior to this date.
• Management emphasizes a "build and execute" phase for the next 12 months, aiming to transition from discovery to clinical proof-of-concept.
• Long-term goal is to establish the platform as a disease-modifying therapy for haploinsufficient CNS disorders, with expectations of unlocking significant value upon clinical success.

Business Segments and Product Lines:

• Core Platform: Antisense oligonucleotide (ASO) technology designed to increase gene expression (up to 2-fold) at the transcriptional level by targeting regulatory RNAs.
• Lead Program (SYNGAP1): First-in-class disease-modifying therapy for SYNGAP1-related intellectual disability and epilepsy (10,000+ U.S. patients); currently in Phase I/II, multiple ascending dose study.
• Pipeline Expansion: Recently advanced SHANK3 program (Phelan-McDermid syndrome; 45,000 U.S. patients) with similar preclinical profiles; several other undisclosed CNS indications in development.
• Strategic Partnership: Collaboration with GSK to target large CNS and kidney diseases outside the company's primary CNS focus, involving ASO discovery and delivery.
• Trial Design: Global Phase I/II study utilizing a 3:1 randomization with a control arm and natural history data; patients will receive three doses over three months.

Market and Competitive Landscape:

• Market Size: SYNGAP1 and SHANK3 represent massive unmet needs comparable to Spinal Muscular Atrophy (SMA) and Cystic Fibrosis in terms of severity.
• Competitive Position: Company claims to be the furthest along in the field; competitive landscape is currently sparse with no approved disease-modifying therapies.
• Differentiation: Unique ability to increase all six isoforms of the target gene in natural proportions, unlike gene therapy or downstream approaches which may not address specific isoform requirements.
• Diagnostics: Diagnostic timelines have shortened from a 10-year odyssey to approximately one year due to increased awareness and whole-genome screening.

Risks and Challenges:

• Clinical Risk: Dependence on early clinical success (Signal-seeking study) to validate the "two-fold" upregulation as therapeutic; lack of prior regulatory precedent for this specific mechanism in this indication.
• Developmental Risk: Need to define optimal biological dose (OBD) and clinical endpoints in a single-gene, rare disease setting without historical controls for efficacy.
• Regulatory Uncertainty: While accelerated approval is a goal, FDA discussions regarding specific endpoints and control arm requirements are ongoing; no guarantee of current path.
• Competition: Management anticipates increased competition as other entities enter the space, though currently views their mechanism as the most biologically rational.

Management Commentary and Tone:

• Tone is confident and execution-focused, describing the company as "deeply undervalued" relative to the potential of their platform and pipeline.
• CEO Josh Mandel-Brem expressed strong belief in the "feature" of the system capping expression at two-fold, mitigating overexpression risks.
• Management emphasizes a "heads down" approach, preferring to under-promise and over-deliver on data timelines.
• Confidence in the platform's mechanical nature (once in the clinic, development is efficient) to support rapid advancement of multiple indications.

Analyst Questions and Answers:

• Efficacy Questions: Confirmed that preclinical data in humanized mice and primates showed complete reversal of cognitive, behavioral, and seizure symptoms.
• Trial Specifics: Clarified that the trial is signal-seeking to find OBD, utilizing a control arm to maintain optionality for accelerated approval discussions.
• Commercial Potential: No specific peak sales figures provided, but described the opportunity as "massive" based on unmet need and comparability to high-value rare disease therapies.
• Platform Scalability: Confirmed the plan to advance indications indication-by-indication due to the genetic specificity of ASOs, though the underlying delivery and mechanism are reusable.

Other Key Points:

• Technology: Uses Gen 2 ASO chemistry (same as Spinraza) with intrathecal delivery to ensure broad distribution to hypothalamic and cortical brain regions.
• Regulatory Status: Clearance obtained in Australia, Argentina, the UK, and the EMA; FDA discussions are in progress.
• Investor Strategy: Management aims to secure value through asset monetization (GSK deals) rather than paying for platform development.
• Disease Context: SYNGAP1 is characterized by severe seizures, cognitive impairment, and behavioral issues; 95-98% of the population is haploinsufficient.